approval
saveOZURDEX (DEXAMETHASONE) — FDA approval
community read0 votes
Sponsor: ABBVIE. Form: IMPLANT. Route: INTRAVITREAL
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalOZURDEX (DEXAMETHASONE) — FDA approvalMar 11, 2026 · 205d ago
- approvalOZURDEX (DEXAMETHASONE) — FDA approvalDec 19, 2022 · 1383d ago
- approvalOZURDEX (DEXAMETHASONE) — FDA approvalOct 21, 2020 · 2172d ago
- approvalOZURDEX (DEXAMETHASONE) — FDA approvalMay 15, 2018 · 3062d ago
- approvalOZURDEX (DEXAMETHASONE) — FDA approvalFeb 5, 2016 · 3892d ago
- approvalOZURDEX (DEXAMETHASONE) — FDA approvalSep 26, 2014 · 4389d ago
- approvalOZURDEX (DEXAMETHASONE) — FDA approvalJun 28, 2014 · 4479d ago
- approvalOZURDEX (DEXAMETHASONE) — FDA approvalFeb 7, 2014 · 4620d ago
same company · ±60 days · 6
- earningsAbbVie Inc. earningsOct 30, 2026
- earningsAbbVie Inc. earningsOct 29, 2026
- earningsAbbVie Inc. earningsJul 31, 2026
- earningsAbbVie Inc. earningsJul 30, 2026
- phase 1 2 completionblinatumomab: AbbVie Inc — blinatumomab (Phase I/II Trial Completion)Apr 30, 2026
- phase 1 2 completionvenetoclax: AbbVie Inc — venetoclax (Phase I/II Trial Completion)Apr 30, 2026
related news · 6
- fiercebiotechBMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 data
- fiercebiotechAbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial
- biospaceMyriad catalysts on deck for obesity’s brightest stars as market continues to accelerate
- fiercebiotechAkeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate
- biospaceAbbVie shares pressured as Q2 I&I beat falls below investor expectations
- biospaceLilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
comments(0)
5-min edit window · permanent after that